Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling